The absence of an association of CDCP1 expression and copy number gains with clinicopathological features or the expression of a basal-like BC marker, such as cytokeratin 5/6 [38], suggests that CDCP1 is already present in early-stage TNBCs, independent of the molecular phenotype of tumor cells. This evidence concerns the gene CDCP1 and neoplasm.